Gc Biopharma Patent-Cliff Exposure & CMS Drug Spending Portfolio

Gc Biopharma (US): 1 reconciled FDA prescription therapies, $1.2M 2024 CMS Part D & Medicaid spend, and $5,960 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies1
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE DateMulti-asset schedule
2024 CMS Total Public Spend$1.2M
2024 Medicare Part D Spend$1.1M
2024 Medicaid Spend$101K
California HCAI SB 17 FilingsSpecialty launch notice ($5,960 intro WAC)